Connection

Stephen Tomlinson to Recombinant Fusion Proteins

This is a "connection" page, showing publications Stephen Tomlinson has written about Recombinant Fusion Proteins.
  1. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
    View in: PubMed
    Score: 0.492
  2. Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis. Clin Exp Immunol. 2015 Mar; 179(3):500-8.
    View in: PubMed
    Score: 0.426
  3. Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol. 2010 Dec 01; 185(11):7007-13.
    View in: PubMed
    Score: 0.315
  4. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009 Jul; 50(7):3056-64.
    View in: PubMed
    Score: 0.281
  5. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
    View in: PubMed
    Score: 0.276
  6. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol. 2008 Jan 15; 180(2):1231-8.
    View in: PubMed
    Score: 0.260
  7. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol. 2006 Sep; 169(3):1039-47.
    View in: PubMed
    Score: 0.236
  8. Complement Inhibition Alleviates Cholestatic Liver Injury Through Mediating Macrophage Infiltration and Function in Mice. Front Immunol. 2021; 12:785287.
    View in: PubMed
    Score: 0.171
  9. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
    View in: PubMed
    Score: 0.166
  10. Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study. Acta Neuropathol Commun. 2021 07 19; 9(1):126.
    View in: PubMed
    Score: 0.166
  11. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem. 2001 Jul 20; 276(29):27290-5.
    View in: PubMed
    Score: 0.164
  12. Complement C3 activation regulates the production of tRNA-derived fragments Gly-tRFs and promotes alcohol-induced liver injury and steatosis. Cell Res. 2019 07; 29(7):548-561.
    View in: PubMed
    Score: 0.142
  13. Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma. Mol Ther. 2018 10 03; 26(10):2379-2396.
    View in: PubMed
    Score: 0.136
  14. Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury. J Neurosci. 2018 03 07; 38(10):2519-2532.
    View in: PubMed
    Score: 0.131
  15. A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Invest Ophthalmol Vis Sci. 2016 Apr; 57(4):1728-37.
    View in: PubMed
    Score: 0.115
  16. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
    View in: PubMed
    Score: 0.106
  17. Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. J Exp Med. 2014 Aug 25; 211(9):1793-805.
    View in: PubMed
    Score: 0.102
  18. A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis. Clin Exp Immunol. 2014 Aug; 177(2):500-8.
    View in: PubMed
    Score: 0.102
  19. Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Rep. 2014 Aug 07; 8(3):818-30.
    View in: PubMed
    Score: 0.102
  20. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. Atherosclerosis. 2014 May; 234(1):237-43.
    View in: PubMed
    Score: 0.100
  21. Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation. 2013 Mar 26; 127(12):1290-9.
    View in: PubMed
    Score: 0.093
  22. Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. Neurosci Lett. 2012 Nov 30; 531(1):35-9.
    View in: PubMed
    Score: 0.090
  23. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
    View in: PubMed
    Score: 0.087
  24. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 2011 Apr; 63(4):1076-85.
    View in: PubMed
    Score: 0.081
  25. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011 Feb; 79(3):331-9.
    View in: PubMed
    Score: 0.079
  26. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol. 2009 Nov 01; 183(9):5928-37.
    View in: PubMed
    Score: 0.073
  27. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol. 2009 Oct 01; 183(7):4764-72.
    View in: PubMed
    Score: 0.073
  28. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest. 2009 Aug; 119(8):2304-16.
    View in: PubMed
    Score: 0.072
  29. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res. 2007 Oct 01; 67(19):9535-41.
    View in: PubMed
    Score: 0.064
  30. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
    View in: PubMed
    Score: 0.055
  31. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003 Jun; 111(12):1875-85.
    View in: PubMed
    Score: 0.047
  32. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.
    View in: PubMed
    Score: 0.041
  33. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.
    View in: PubMed
    Score: 0.039
  34. A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
    View in: PubMed
    Score: 0.023
  35. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
    View in: PubMed
    Score: 0.021
  36. Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol. 2011 Oct; 45(4):834-42.
    View in: PubMed
    Score: 0.020
  37. A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J. 2010 Feb 09; 7:30.
    View in: PubMed
    Score: 0.019
  38. Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol. 2008 Sep; 74(3):574-84.
    View in: PubMed
    Score: 0.017
  39. Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment. Mol Immunol. 2008 May; 45(9):2570-80.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.